

EXECUTIVE OFFICE OF THE PRESIDENT

OFFICE OF NATIONAL DRUG CONTROL POLICY

2 CFR 3603 *et seq.* and 21 CFR 1400 *et seq.*

Semiannual Regulatory Agenda

AGENCY: Office of National Drug Control Policy.

ACTION: Semiannual regulatory agenda.

SUMMARY: The Regulatory Flexibility Act of 1980 and Executive Order 12866 require the semiannual issuance of an inventory of rulemaking actions under development throughout the Department, offering for public review summarized information about forthcoming regulatory actions.

FOR FURTHER INFORMATION CONTACT: For general information, please contact Anthony D. Jones, Acting General Counsel, Office of General Counsel, Office of National Drug Control Policy, Executive Office of the President, 1800 G Street NW, Washington, DC 20503 or by telephone (202) 395-3493.

SUPPLEMENTARY INFORMATION:

The Office of National Drug Control Policy (ONDCP), a component of the Executive Office of the President, was established by the Anti-Drug Abuse Act of 1988. The principal purpose of ONDCP is to establish policies, priorities, and objectives for the Nation's drug control program. The goals of the program are to reduce illicit drug use, manufacturing, and trafficking, drug-related crime and violence, and drug-related health consequences. To achieve these goals, the Director of ONDCP is charged with producing the National Drug Control Strategy (Strategy) to coordinate the national anti-drug efforts.

By law, the Director of ONDCP also evaluates, coordinates, and oversees both the international and domestic anti-drug efforts of Executive Branch Agencies and ensures that such

efforts are consistent with the National Drug Control Strategy and sustain and complement State and local anti-drug activities. The Director advises the President regarding changes in the organization, management, budgeting, and personnel of Federal Agencies that could affect the Nation's anti-drug efforts; and regarding Federal agency compliance with their obligations under the Strategy.

This Agenda presents the rulemaking activities that the ONDCP currently expects to undertake this year to advance the National Drug Control Strategy and its broader mission. Pursuant to the Substance Use–Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act), 21 U.S.C. 1708(c), ONDCP will propose *Criteria for Designating Emerging Drug Threats* in the United States (RIN 3201-AA02). The Agency issued an Advance Notice of Proposed Rulemaking on May 15, 2020 (85 Fed. Reg.) and solicited comments about the proposed criteria. The Agency plans to issue a Notice of Proposed Rulemaking in Fall 2020. ONDCP is also in the process of updating its *Freedom of Information Act and Privacy Act* regulations for consistency with various laws including the FOIA Improvements Act of 2016, 5 U.S.C. 552a (RIN 3201-AA01). The Agency issued a Notice of Proposed Rulemaking on May 22, 2020 (85 Fed. Reg. 31087) and plans to publish a Final Rule concerning our Freedom of Information Act and Privacy Act regulations in September 2020.

NAME: Anthony D. Jones,
Acting General Counsel.